128 related articles for article (PubMed ID: 37987797)
1. Correction: In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning.
Aliabadi A; Haghshenas MR; Kiani R; Koohi-Hosseinabadi O; Purkhosrow A; Pirsalami F; Panjehshahin MR; Erfani N
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2525. PubMed ID: 37987797
[No Abstract] [Full Text] [Related]
2. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer.
Nygren P; Fryknäs M; Agerup B; Larsson R
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2133-40. PubMed ID: 24135855
[TBL] [Abstract][Full Text] [Related]
3. Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer.
Nygren P; Larsson R
Acta Oncol; 2014 Mar; 53(3):427-8. PubMed ID: 24160353
[No Abstract] [Full Text] [Related]
4. The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation.
Blom K; Senkowski W; Jarvius M; Berglund M; Rubin J; Lenhammar L; Parrow V; Andersson C; Loskog A; Fryknäs M; Nygren P; Larsson R
Immunopharmacol Immunotoxicol; 2017 Aug; 39(4):199-210. PubMed ID: 28472897
[TBL] [Abstract][Full Text] [Related]
5. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
Hegazy SK; El-Azab GA; Zakaria F; Mostafa MF; El-Ghoneimy RA
Life Sci; 2022 Jun; 299():120536. PubMed ID: 35385794
[TBL] [Abstract][Full Text] [Related]
6. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers.
Meco D; Attinà G; Mastrangelo S; Navarra P; Ruggiero A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674870
[TBL] [Abstract][Full Text] [Related]
7. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.
Rushworth LK; Hewit K; Munnings-Tomes S; Somani S; James D; Shanks E; Dufès C; Straube A; Patel R; Leung HY
Br J Cancer; 2020 Feb; 122(4):517-527. PubMed ID: 31844184
[TBL] [Abstract][Full Text] [Related]
8. Development of colon targeted drug delivery systems for mebendazole.
Krishnaiah YS; Veer Raju P; Dinesh Kumar B; Bhaskar P; Satyanarayana V
J Control Release; 2001 Nov; 77(1-2):87-95. PubMed ID: 11689262
[TBL] [Abstract][Full Text] [Related]
9. Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death.
Petersen JSSM; Baird SK
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2945-2953. PubMed ID: 34148157
[TBL] [Abstract][Full Text] [Related]
10. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.
Elayapillai S; Ramraj S; Benbrook DM; Bieniasz M; Wang L; Pathuri G; Isingizwe ZR; Kennedy AL; Zhao YD; Lightfoot S; Hunsucker LA; Gunderson CC
Gynecol Oncol; 2021 Jan; 160(1):302-311. PubMed ID: 33131904
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers.
Krishnaiah YS; Veer Raju P; Dinesh Kumar B; Satyanarayana V; Karthikeyan RS; Bhaskar P
J Control Release; 2003 Feb; 88(1):95-103. PubMed ID: 12586507
[TBL] [Abstract][Full Text] [Related]
12. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
13. Development and in vitro characterization of mebendazole delayed release tablet for colonic drug delivery.
Baviskar D; Rajput A; Bare K; Biranwar Y; Chaudhari H; Narkhede D; Jain D
Pak J Pharm Sci; 2014 Mar; 27(2):249-53. PubMed ID: 24577910
[TBL] [Abstract][Full Text] [Related]
14. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
[TBL] [Abstract][Full Text] [Related]
15. Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer.
Williamson T; Mendes TB; Joe N; Cerutti JM; Riggins GJ
Endocr Relat Cancer; 2020 Mar; 27(3):123-136. PubMed ID: 31846433
[TBL] [Abstract][Full Text] [Related]
16. Exposure of
Rocha OB; E Silva KSF; Moraes D; Borges CL; Soares CMA; Pereira M
Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830117
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro.
Choi HS; Ko YS; Jin H; Kang KM; Ha IB; Jeong H; Song HN; Kim HJ; Jeong BK
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500557
[TBL] [Abstract][Full Text] [Related]
18. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
Skibinski CG; Williamson T; Riggins GJ
J Neurooncol; 2018 Dec; 140(3):529-538. PubMed ID: 30414098
[TBL] [Abstract][Full Text] [Related]
19. Diclofenac and metformin synergistic dose dependent inhibition of hamster fibrosarcoma, rescued with mebendazole.
Popović DJ; Popović KJ; Miljković D; Popović JK; Lalošević D; Poša M; Dolićanin Z; Čapo I
Biomed Pharmacother; 2023 Nov; 167():115528. PubMed ID: 37738800
[TBL] [Abstract][Full Text] [Related]
20. Anticancer potential of mebendazole against chronic myeloid leukemia:
Daniel JP; Mesquita FP; Da Silva EL; de Souza PFN; Lima LB; de Oliveira LLB; de Moraes MEA; Moreira-Nunes CFA; Burbano RMR; Zanatta G; Montenegro RC
Front Pharmacol; 2022; 13():952250. PubMed ID: 36091760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
